Lynx1 Capital Management LP — 13F Holdings & Portfolio
CIK 1910456 · latest 13F-HR filed 2026-08-13
Lynx1 Capital Management LP manages $865.5M in 13F-reported U.S. long-equity assets across 27 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are GHRS (41.19%), CGEM (18.86%), STOK (15.27%). Quarter over quarter (versus its 2026-06-30 filing) the fund opened 4 new positions, exited 0, added to 0, and trimmed 0.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
SUITE 301 PMB 1202
DORADO 00646
$865.5M
Long-equity book
27
Distinct positions
2026-06-30
Filed 2026-08-13
+4 / −0 / ↑0 / ↓0
vs 2026-06-30
| Name | Title / Status | Ownership | Type |
|---|
New Positions
- GH RESEARCH PLC$356.5M
- PROQR THRAPEUTICS N V$969.8K
- ABSCI CORPORATION$246.2K
- IMMATICS N.V$235.4K
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | GH RESEARCH PLC | GHRS | G3855L106 | $356.5M | 41.19% | 13,263,288 | SH |
| 2 | CULLINAN THERAPEUTICS INC | CGEM | 230031106 | $163.2M | 18.86% | 8,963,500 | SH |
| 3 | STOKE THERAPEUTICS INC | STOK | 86150R107 | $132.1M | 15.27% | 4,038,404 | SH |
| 4 | AGIOS PHARMACEUTICALS INC | AGIO | 00847X104 | $126.5M | 14.62% | 3,408,937 | SH |
| 5 | C4 THERAPEUTICS INC | CCCC | 12529R107 | $34.2M | 3.95% | 7,326,691 | SH |
| 6 | KORRO BIO INC | KRRO | 500946108 | $20.3M | 2.34% | 1,538,296 | SH |
| 7 | TSCAN THERAPEUTICS INC | TCRX | 89854M101 | $7.9M | 0.91% | 8,019,148 | SH |
| 8 | PRECISION BIOSCIENCES INC | DTIL | 74019P207 | $7.5M | 0.86% | 950,466 | SH |
| 9 | NEUPHORIA THERAPEUTICS INC | NEUP | 64136E102 | $3.8M | 0.44% | 875,328 | SH |
| 10 | PASSAGE BIO INC | PASG | 702712209 | $3.3M | 0.38% | 673,759 | SH |
| 11 | CG ONCOLOGY INC | CGON | 156944100 | $2.2M | 0.26% | 31,391 | SH |
| 12 | PLIANT THERAPEUTICS INC | PLRX | 729139105 | $2.0M | 0.24% | 1,798,070 | SH |
| 13 | ENTRADA THERAPEUTICS INC | TRDA | 29384C108 | $1.3M | 0.15% | 178,606 | SH |
| 14 | VYNE THERAPEUTICS INC | VYNE | 92941V308 | $1.1M | 0.12% | 1,628,700 | SH |
| 15 | PROQR THRAPEUTICS N V | PRQR | N71542109 | $969.8K | 0.11% | 521,413 | SH |
| 16 | TRAWS PHARMA INC | TRAW | 68232V884 | $471.8K | 0.05% | 559,470 | SH |
| 17 | FOGHORN THERAPEUTICS INC | FHTX | 344174107 | $300.5K | 0.03% | 61,588 | SH |
| 18 | DENALI THERAPEUTICS INC | DNLI | 24823R105 | $299.8K | 0.03% | 11,658 | SH |
| 19 | XENCOR INC | XNCR | 98401F105 | $292.9K | 0.03% | 18,194 | SH |
| 20 | ABSCI CORPORATION | ABSI | 00091E109 | $246.2K | 0.03% | 21,245 | SH |
| 21 | WEREWOLF THERAPEUTICS INC | HOWL | 95075A107 | $236.7K | 0.03% | 657,786 | SH |
| 22 | IMMATICS N.V | IMTX | N44445109 | $235.4K | 0.03% | 23,236 | SH |
| 23 | AVALO THERAPEUTICS INC | AVTX | 05338F306 | $186.6K | 0.02% | 10,100 | SH |
| 24 | BOLT BIOTHERAPEUTICS INC | BOLT | 097702203 | $118.6K | 0.01% | 30,800 | SH |
| 25 | NUVATION BIO INC | NUVB | 67080N101 | $91.0K | 0.01% | 16,029 | SH |
| 26 | EUPRAXIA PHARMACEUTICALS INC | EPRX | 29842P105 | $66.1K | 0.01% | 10,000 | SH |
| 27 | INHIBIKASE THERAPEUTICS INC | IKT | 45719W205 | $40.6K | 0.00% | 20,000 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-12 | $507.6M | 23 | 0001910456-26-000003 |
| 2026-06-30 | 2026-08-13 | $865.5M | 27 | 0001910456-26-000004 |
| 2026-03-31 | 2026-05-04 | $632.7M | 23 | 0001910456-26-000002 |
| 2025-12-31 | 2026-02-17 | $494.0M | 22 | 0001910456-26-000001 |